A Phase II Comparative Study of ABI-007 in Patients with Metastatic Breast Cancer.

A Phase II Comparative Study between Weekly Administration of ABI-007 and Tri-weekly Administration of Docetaxel in Patients with Metastatic Breast Cancer.

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220890

Enrollment

192

Registered

2009-10-05

Start date

2009-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic breast cancer

Interventions

investigational material(s) Generic name etc : ABI-007 INN of investigational material : paclitaxel Therapeutic category code : 424 Antineoplastic preparations extracted from plants Dosage and Adminis

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: No history of chemotherapy for metastatic breast cancer No over-expression of HER2 by IHC or FISH

Exclusion criteria

Exclusion criteria: Recurrent disease within 12 months following the end of neo-adjuvant or adjuvant chemotherapy with a taxane-containing regimen

Design outcomes

Primary

Measure	Time frame
Progression free survival RECIST	—

Secondary

Measure	Time frame
Response rate, Time to treatment failure, Time to progression, Overall survival RECIST, other.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026